Radiotherapy Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (External Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiation Therapy), By Application (kin & Lip Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Others), By End-User (Hospitals, Research Institutes, Ambulatory and Radiotherapy Centers), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.81 Billion
CAGR (2026-2031)	8.73%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 11.25 Billion

Market Overview

The Global Radiotherapy Market is projected to grow from USD 6.81 Billion in 2025 to USD 11.25 Billion by 2031 at a 8.73% CAGR. Radiotherapy constitutes a clinical modality that utilizes ionizing radiation to damage the DNA of cancerous tissues and thereby inhibit cellular replication for curative or palliative purposes. The primary driver supporting market growth is the rising global incidence of oncological disorders combined with demographic shifts towards an aging population that is more susceptible to malignancies. Furthermore, the expansion of healthcare reimbursement coverage in developing regions provides a fundamental structural impetus for market broadening that remains distinct from transient technological shifts or product trends.

Despite these favorable conditions, the high acquisition and operational costs associated with radiation delivery systems present a substantial barrier that impedes widespread adoption in markets with limited financial resources. This economic constraint exacerbates the gap between infrastructure supply and the escalating patient demand. According to the 'American Cancer Society', in '2025', 'a total of 2,041,910 new cancer cases are projected to be diagnosed in the United States'. This statistic underscores the critical necessity for economically viable solutions to address the mounting burden of disease facing the healthcare sector.

Key Market Drivers

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into treatment planning and delivery systems is fundamentally reshaping the market by addressing critical workflow inefficiencies and enhancing therapeutic precision. These technologies enable the automation of complex tasks such as contouring and dose calculation, significantly reducing the time required between diagnosis and treatment initiation while minimizing human error. This operational acceleration is vital for clinics facing high patient volumes, allowing for adaptive therapies that adjust to anatomical changes in real-time. According to GE HealthCare, in September 2025, early adopters of their AI-supported Intelligent Radiation Therapy (iRT) solution reported a reduction in the time from simulation to treatment planning from seven days to just seven minutes. Such dramatic efficiency gains drive the replacement of legacy systems with AI-enabled platforms, fostering market growth through high-value equipment upgrades.

Parallel to technological advancements, supportive government initiatives and funding for healthcare infrastructure in emerging and established markets serve as a robust catalyst for the expansion of radiotherapy accessibility. Public sector investment is increasingly directed towards modernizing oncology departments and bridging the equipment gap in underserved regions, thereby directly stimulating procurement activities for linear accelerators and associated software. For instance, according to the UK Government, in May 2025, a £70 million investment was confirmed to fund the rollout of new radiotherapy machines across 28 hospitals to cut waiting lists and improve cancer care. This capital injection exemplifies the critical role of state-level support in sustaining market momentum. Furthermore, the scale of existing infrastructure continues to grow to meet global demand; according to Elekta, in July 2025, the company maintained an installed base of more than 7,500 devices and software solutions at clinics worldwide, reflecting the expanding footprint of radiation medicine.

Download Free Sample Report

Key Market Challenges

The significant acquisition and operational costs associated with advanced radiation delivery systems constitute a substantial barrier impeding the growth of the global radiotherapy market. These sophisticated platforms, particularly linear accelerators and proton therapy units, require massive capital expenditure that extends beyond the initial purchase to include specialized infrastructure, ongoing maintenance, and highly skilled personnel. In markets with finite financial resources, this high barrier to entry prevents healthcare providers from scaling their capabilities to match patient volume. Consequently, many facilities are unable to upgrade aging equipment or expand their footprint, directly stifling the adoption of newer technologies essential for market expansion.

This financial strain is further compounded by contracting reimbursement models, which destabilize the return on investment necessary to justify such high-value procurements. When operational revenue declines, the economic viability of maintaining a state-of-the-art radiotherapy department is compromised, causing providers to freeze capital investments. According to the 'American Society for Radiation Oncology', in '2025', 'the Medicare Physician Fee Schedule finalized a reimbursement reduction of approximately 2.8 percent for radiation oncology services'. Such fiscal contractions create a hostile economic environment that hampers infrastructure development, thereby restricting the market’s ability to bridge the widening gap between supply and the escalating global demand for cancer care.

Key Market Trends

The accelerated adoption of MRI-Guided Linear Accelerators is transforming the market by enabling real-time visualization of soft tissue during radiation delivery, a capability absent in conventional X-ray guided systems. This technology allows clinicians to reduce margins and safely escalate doses to tumors located near critical organs, driving procurement in high-end academic centers and specialized oncology networks. The clinical validity of this modality is increasingly supported by robust trial data, which validates the high capital investment required for these platforms. According to Elekta, May 2025, in the 'Clinical trial shows more precise radiotherapy using Elekta Unity MR-Linac preserves sexual function in men with prostate cancer' press release, preliminary results from the ERECT trial demonstrated that MR-guided radiotherapy significantly preserved patient quality of life, reducing the incidence of erectile dysfunction at six months to 6% compared to 21% with conventional methods.

The expansion of Proton and Carbon Ion Therapy infrastructure represents a parallel shift toward particle-based modalities that offer superior depth-dose characteristics for treating deep-seated malignancies. Despite the substantial initial capital requirements, the market is witnessing sustained investment in these facilities, driven by their ability to spare healthy tissue in pediatric and complex adult cases. This segment is growing as manufacturers successfully convert heavy equipment order backlogs into operational centers, validating the economic feasibility of these massive projects. According to IBA, March 2025, in the 'IBA reports solid Full Year 2024 results' press release, the company reported a 7% year-over-year increase in total net sales to €498.2 million, a growth trajectory largely sustained by the strong execution and conversion of its proton therapy and accelerator backlog.

Segmental Insights

The Hospitals segment represents the fastest growing category within the Global Radiotherapy Market, driven by the centralization of complex cancer treatments in well-equipped medical facilities. This expansion is largely attributed to the high capital expenditure required for radiotherapy devices and the specialized infrastructure needed for operation, which hospitals are best positioned to support. Furthermore, rising patient admissions due to increasing global cancer prevalence compel hospitals to expand their oncology departments. Consequently, public and private healthcare investments are prioritizing the modernization of hospital-based radiation therapy units to meet this escalating demand efficiently.

Regional Insights

North America holds the leading position in the global radiotherapy market, driven by the high incidence of cancer and the widespread adoption of modern treatment technologies. The region benefits from a well-developed healthcare infrastructure and the substantial presence of major medical device manufacturers. Furthermore, supportive regulatory frameworks provided by the U.S. Food and Drug Administration streamline the approval of new devices, while favorable reimbursement policies improve patient access to care. These elements combined with significant healthcare expenditure ensure North America remains the dominant revenue contributor globally.

Recent Developments

• In December 2025, GE HealthCare and Mayo Clinic unveiled a strategic research collaboration known as GEMINI-RT, dedicated to advancing personalized radiation therapy. The initiative focused on integrating artificial intelligence, data analytics, and multimodal therapies to enhance the precision and efficiency of cancer care. Key areas of the partnership included the development of automated tools for treatment planning, predictive oncology models, and improved patient monitoring solutions. By combining clinical insights with engineering expertise, the organizations aimed to create a more connected care continuum that would streamline workflows and facilitate data-driven decision-making for radiation oncologists globally.
• In January 2025, RefleXion Medical announced the launch of the BIOGUIDE-X2 clinical study to evaluate the performance of its SCINTIX biology-guided radiotherapy for new clinical indications. Conducted in collaboration with Hackensack Meridian John Theurer Cancer Center and Georgetown’s Lombardi Comprehensive Cancer Center, the research focused on assessing the technology's efficacy in treating patients with metastatic cancers. The study aimed to leverage the system's unique ability to use emissions from tumors to guide radiation delivery in real-time. This breakthrough research was intended to validate the platform’s potential to manage complex, moving tumors and expand access to precise treatment for late-stage cancer patients.
• In June 2024, Accuray Incorporated entered into a strategic agreement with TrueNorth Medical Physics to provide expanded support services to radiation oncology departments. Under the terms of the collaboration, the partner organization agreed to offer physics, dosimetry, and commissioning support as an extension of hospital teams, utilizing on-site, remote, or hybrid models. This partnership was established to address staffing challenges within clinics and ensure that healthcare providers could maximize the utility of the company’s treatment delivery systems. The initiative aimed to facilitate the adoption of advanced radiotherapy techniques and maintain efficient patient treatment schedules across various clinical settings.
• In May 2024, Elekta launched Evo, a new high-definition adaptive computed tomography-linear accelerator, at the Annual Congress of the European Society for Radiotherapy and Oncology. The system was designed to provide both offline and online adaptive radiation therapy, utilizing artificial intelligence to enhance image quality and anatomical visualization. By integrating these advanced capabilities, the platform aimed to allow clinicians to personalize treatments more effectively and adjust to changes in a patient’s anatomy. The company highlighted that the technology would support improved standard image-guided radiation therapy and streamline clinical workflows through automated planning and faster dose calculation features.

Key Market Players

• Canon Medical Systems Corporation
• GE Healthcare Technologies Inc.
• Elekta AB
• ViewRay Technologies, Inc.
• Mevion Medical Systems Inc.
• BEBIG Medical GmbH
• Siemens Healthineers AG
• Accuray Incorporated
• Isoray Inc.
• Hitachi, Ltd.
• ALCEN Group

By Type	By Application	By End-User	By Region
External Beam Radiation Therapy Internal Radiation Therapy Systemic Radiation Therapy	kin & Lip Cancer Breast Cancer Prostate Cancer Cervical Cancer Lung Cancer Others	Hospitals Research Institutes Ambulatory Radiotherapy Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Radiotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Radiotherapy Market, By Type:

• External Beam Radiation Therapy
• Internal Radiation Therapy
• Systemic Radiation Therapy

• Radiotherapy Market, By Application:

• kin & Lip Cancer
• Breast Cancer
• Prostate Cancer
• Cervical Cancer
• Lung Cancer
• Others

• Radiotherapy Market, By End-User:

• Hospitals
• Research Institutes
• Ambulatory
• Radiotherapy Centers

• Radiotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE